Cargando…

Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. It is often associated with activating mutations in KRAS leading to deregulation of major signaling pathways as the RAS-RAF-MAPK and PI3K-Akt. However, the therapeutic options for CRC patients harboring somatic KRAS mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandes, Maria Sofia, Melo, Soraia, Velho, Sérgia, Carneiro, Patrícia, Carneiro, Fátima, Seruca, Raquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356572/ https://www.ncbi.nlm.nih.gov/pubmed/27602501 http://dx.doi.org/10.18632/oncotarget.11843

Ejemplares similares

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
por: Velho, Sérgia, et al.
Publicado: (2008)

Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2022)

S100P is a molecular determinant of E-cadherin function in gastric cancer
por: Carneiro, Patrícia, et al.
Publicado: (2019)

The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression
por: Moreira, Ana Margarida, et al.
Publicado: (2020)

Clinical spectrum and pleiotropic nature of CDH1 germline mutations
por: Figueiredo, Joana, et al.
Publicado: (2019)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

Modulation of Fibroblast Phenotype by Colorectal Cancer Cell-Secreted Factors Is Mostly Independent of Oncogenic KRAS
por: Dias Carvalho, Patrícia, et al.
Publicado: (2022)

Quantification of mutant E-cadherin using bioimaging analysis of in situ fluorescence microscopy. A new approach to CDH1 missense variants
por: Sanches, João Miguel, et al.
Publicado: (2015)

Dissecting the signaling pathways associated with the oncogenic activity of MLK3 P252H mutation
por: Velho, Sérgia, et al.
Publicado: (2014)

Targeting the PI3K signaling pathway in KRAS mutant colon cancer
por: Hong, Suntaek, et al.
Publicado: (2015)

The ECM and tissue architecture are major determinants of early invasion mediated by E-cadherin dysfunction
por: Melo, Soraia, et al.
Publicado: (2023)

Class IA PI3K regulatory subunits: p110-independent roles and structures
por: Fox, Millie, et al.
Publicado: (2020)

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
por: Zhang, Lei, et al.
Publicado: (2020)

PI3K activation is enhanced by FOXM1D binding to p110 and p85 subunits
por: Wang, Qi, et al.
Publicado: (2020)

A machine learning approach for single cell interphase cell cycle staging
por: Narotamo, Hemaxi, et al.
Publicado: (2021)

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice
por: Deng, Lisa, et al.
Publicado: (2017)

Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer
por: Melo, Soraia, et al.
Publicado: (2017)

Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway
por: Liu, Yanfei, et al.
Publicado: (2022)

Decellularized Colorectal Cancer Matrices as Bioactive Scaffolds for Studying Tumor-Stroma Interactions
por: Marques-Magalhães, Ângela, et al.
Publicado: (2022)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

PI3K p110β subunit in leptin receptor expressing cells is required for the acute hypophagia induced by endotoxemia
por: Borges, Beatriz C., et al.
Publicado: (2016)

Geometric compensation applied to image analysis of cell populations with morphological variability: a new role for a classical concept
por: Figueiredo, Joana, et al.
Publicado: (2018)

Epidermal growth factor receptor structural alterations in gastric cancer
por: Moutinho, Cátia, et al.
Publicado: (2008)

Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2016)

Intricate Macrophage-Colorectal Cancer Cell Communication in Response to Radiation
por: Pinto, Ana T., et al.
Publicado: (2016)

Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden
por: Figueiredo, Joana, et al.
Publicado: (2021)

Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model
por: Carneiro, Tatiana J., et al.
Publicado: (2022)

KRAS mutation‐independent downregulation of MAPK/PI3K signaling in colorectal cancer
por: Lam, Kuen Kuen, et al.
Publicado: (2022)

Role of p110a subunit of PI3-kinase in skeletal muscle mitochondrial homeostasis and metabolism
por: Li, Mengyao Ella, et al.
Publicado: (2019)

The PI-3-Kinase P110α Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis
por: Montes-Casado, María, et al.
Publicado: (2021)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Author Correction: Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2020)

LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β
por: Zhao, Wei‐Jun, et al.
Publicado: (2021)

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
por: Caiola, Elisa, et al.
Publicado: (2016)

Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies
por: Kuracha, Murali R., et al.
Publicado: (2017)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Structural and immunological characterization of the myosin-like 110-kD subunit of the intestinal microvillar 110K-calmodulin complex: evidence for discrete myosin head and calmodulin-binding domains
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_drbui2u6im377dpq4bva9ih7rj